Immunoprecise EBITDA Margin Trend from 2010 to 2022

IPA
 Stock
  

USD 3.99  0.15  3.62%   

Immunoprecise Antibodies EBITDA Margin is increasing over the years with slightly volatile fluctuation. EBITDA Margin is expected to dwindle to -0.1. From 2010 to 2022 Immunoprecise Antibodies EBITDA Margin quarterly data regression line had arithmetic mean of(0.28) and significance of  0.001607. Immunoprecise Antibodies Cost of Revenue is projected to increase significantly based on the last few years of reporting. The past year's Cost of Revenue was at 7.33 Million. The current year Interest Expense is expected to grow to about 596.1 K, whereas Consolidated Income is forecasted to decline to (9.1 M).
  
Refresh
Check Immunoprecise Antibodies financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Immunoprecise main balance sheet or income statement drivers, such as Cost of Revenue of 7.3 M, Gross Profit of 11.8 M or Interest Expense of 596.1 K, as well as many exotic indicators such as Asset Turnover of 0.36, Book Value per Share of 3.25 or Current Ratio of 9.98. Immunoprecise financial statements analysis is a perfect complement when working with Immunoprecise Antibodies Valuation or Volatility modules. It can also supplement various Immunoprecise Antibodies Technical models. Please see the analysis of Immunoprecise Antibodies Correlation against competitors.

Immunoprecise Antibodies Quarterly EBITDA Margin

(0.53)

Share

Immunoprecise EBITDA Margin Breakdown

Showing smoothed EBITDA Margin of Immunoprecise Antibodies with missing and latest data points interpolated. Measures the ratio between a company's Earnings Before Interest Taxes and Depreciation Amortization EBITDA and Revenues.Immunoprecise Antibodies' EBITDA Margin historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Immunoprecise Antibodies' overall financial position and show how it may be relating to other accounts over time.
EBITDA Margin10 Years Trend
Increasing
Slightly volatile
 EBITDA Margin 
Share
      Timeline 

Immunoprecise EBITDA Margin Regression Statistics

Arithmetic Mean(0.28)
Coefficient Of Variation(50.91)
Mean Deviation 0.12
Median(0.37)
Standard Deviation 0.14
Sample Variance 0.019903
Range 0.33
R-Value 0.78
Mean Square Error 0.008454
R-Squared 0.61
Significance 0.001607
Slope 0.028308
Total Sum of Squares 0.24

Immunoprecise EBITDA Margin History

2019 -0.032
2020 -0.079
2021 -0.0908
2022 -0.098

About Immunoprecise Antibodies Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Immunoprecise Antibodies income statement, its balance sheet, and the statement of cash flows. Immunoprecise Antibodies investors use historical funamental indicators, such as Immunoprecise Antibodies's EBITDA Margin, to determine how well the company is positioned to perform in the future. Although Immunoprecise Antibodies investors may use each financial statement separately, they are all related. The changes in Immunoprecise Antibodies's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Immunoprecise Antibodies's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Immunoprecise Antibodies Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Immunoprecise Antibodies. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for 2022
EBITDA Margin(0.09) (0.1) 
Earnings Before Interest Taxes and Depreciation Amortization EBITDA-1.6 M-1.8 M
ImmunoPrecise Antibodies Ltd., together with its subsidiaries, engages in antibody production and related services in the United States, Canada, Europe, and internationally. ImmunoPrecise Antibodies Ltd. was incorporated in 1983 and is based in Victoria, Canada. Immunoprecise Antibodies operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 73 people.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Immunoprecise Antibodies without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Piotroski F Score Now

   

Piotroski F Score

Get Piotroski F Score based on binary analysis strategy of nine different fundamentals
All  Next Launch Module

Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Immunoprecise Antibodies using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please see the analysis of Immunoprecise Antibodies Correlation against competitors. Note that the Immunoprecise Antibodies information on this page should be used as a complementary analysis to other Immunoprecise Antibodies' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Content Syndication module to quickly integrate customizable finance content to your own investment portal.

Complementary Tools for Immunoprecise Stock analysis

When running Immunoprecise Antibodies price analysis, check to measure Immunoprecise Antibodies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunoprecise Antibodies is operating at the current time. Most of Immunoprecise Antibodies' value examination focuses on studying past and present price action to predict the probability of Immunoprecise Antibodies' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Immunoprecise Antibodies' price. Additionally, you may evaluate how the addition of Immunoprecise Antibodies to your portfolios can decrease your overall portfolio volatility.
Fund Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Go
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Go
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Go
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Go
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Go
Money Managers
Screen money managers from public funds and ETFs managed around the world
Go
Is Immunoprecise Antibodies' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Immunoprecise Antibodies. If investors know Immunoprecise will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Immunoprecise Antibodies listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
94.4 M
Quarterly Revenue Growth YOY
0.066
Return On Assets
-0.19
Return On Equity
-0.43
The market value of Immunoprecise Antibodies is measured differently than its book value, which is the value of Immunoprecise that is recorded on the company's balance sheet. Investors also form their own opinion of Immunoprecise Antibodies' value that differs from its market value or its book value, called intrinsic value, which is Immunoprecise Antibodies' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Immunoprecise Antibodies' market value can be influenced by many factors that don't directly affect Immunoprecise Antibodies' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Immunoprecise Antibodies' value and its price as these two are different measures arrived at by different means. Investors typically determine Immunoprecise Antibodies value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Immunoprecise Antibodies' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.